Primer: Vigil Neuroscience (VIGL US) - Aug 2026
Vigil Neuroscience is being acquired by Sanofi in a deal expected to close in Q3 2025, fundamentally altering the company's structure and...
89 Views
Biopharma Week in Review - FDA Provides Some Certainty for Vaccines; ASCO Abstracts Snippets
Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.
255 Views
Biopharma Week in Review - January 27, 2025
Academia was troubled last week by Trump’s broad pause on external communications from federal health agencies, disrupting study sections (NIH),...
277 Views
Biopharma Week in Review - November 4, 2024
Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.
293 Views
Vigil Neuroscience Inc (VIGL) - Monday, Jul 7, 2025
Sanofi is acquiring Vigil Neuroscience for $8 per share plus a potential $2 CVR, offering investors a low-risk opportunity amid uncertainties in...
358 Views